Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Journal of Infection and Public Health

Volumn 9, Issue 3, 2016, Pages 227-230

  Rossignol, Jean François ^a  

^a Romark Laboratories   (United States)

Author keywords

Coronavirus; MERS CoV; Nitazoxanide; Treatment

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NITAZOXANIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT; THIAZOLE DERIVATIVE;

ARTICLE; CORONAVIRIDAE INFECTION; CYTOKINE PRODUCTION; DRUG RESEARCH; HUMAN; IN VITRO STUDY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MONOTHERAPY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; ANIMAL; CLINICAL TRIAL (TOPIC); CORONAVIRUS INFECTIONS; DISEASE MODEL; DRUG EFFECTS; PHYSIOLOGY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; THIAZOLES; VIRUS REPLICATION;

EID: 84963535588     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2016.04.001     Document Type: Article

References (9)

1. Zumla A., Azhar E.I., Arabi Y., Alotaibi B., Rao M., McCloskey B., et al. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. Int J Infect Dis 2015, 40:71-74.
2. Rossignol J.F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 2014, 110:94-103.
3. Rossignol J.F., La Frazia S., Chiappa L., Ciucci A., Santoro M.G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level. J Biol Chem 2009, 284:29798-29808.
4. Belardo G., Cenciarelli O., La Frazia S., Rossignol J.F., Santoro M.G. The novel anti-influenza nitazoxanide acts in synergism with neuraminidase inhibitors. Antimicrob Agents Chemother 2015, 59:1061-1069.
5. Lam K.K.Y., Zheng X., Forestieri R., Balgi A.D., Nodwell M., Volett S., et al. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog 2012, 8:e1002691.
6. ® (nitazoxanide) prescribing information 2007.
7. Cao J., Forrest J.C., Zhang X. A screen of the NIH collection small molecule library identifies potential coronavirus. Antiviral Res 2015, 114:1-10.
8. Hong S.K., Kim H.G., Chong C.S., Choi I.S., Lee J.B., Park S.Y. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. Int Immunopharmacol 2012, 13:23-27.
9. Haffizulla J., Hartman A., Hoppers M., Resnick H., Samudrala S., Ginocchio C., et al. A randomized, double-blind, placebo controlled clinical trial of nitazoxanide in adults and adolescents with acute uncomplicated influenza. Lancet Infect Dis 2014, 14:609-618.